Detection of Circulating Tumor Cells in Breast Cancer Patients: Prognostic Predictive Role

Türker, İbrahim; Üyetürk, Ümmügül; Sönmez, Özlem; Öksüzoğlu, Berna; Helvacı, Kaan; Arslan, Ulku Yalcintas; Budakoğlu, Burçin; Alkış, Necati; Aksoy, Sercan; Zengi̇n, Nurullah

doi:10.7314/apjcp.2013.14.3.1601

Cited by 9 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

show abstract

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…From a clinical perspective, disease assessment by CTCs detection in the peripheral blood, with the merit of time- and cost-saving, appears acceptable to patients, and may be readily repeated as a monitoring tool. To date, encouraging results concerning the association between CTC-positive and clinical outcomes in patients with breast, prostate, and colorectal cancer have been recently published [ 45 – 47 ]. However, there are currently few studies on the clinical relevance of CTC-positive with UC that have included data synthesis.…”

Section: Discussionmentioning

confidence: 99%

The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies

et al. 2017

View full text Add to dashboard Cite

There are inconsistent conclusions in the association between circulating tumor cells (CTCs) and urothelial cancer (UC). We performed a meta-analysis to assess the prognostic and diagnostic value of CTCs in UC. We search Medline, Embase and Web of science for relevant studies. The study was set up according to the inclusion/exclusion criteria. 30 published studies with a total of 2161 urothelial cancer patients were included. Meta-analysis showed that CTC-positive was significantly associated with tumor stage (≤ II vs III, IV) (OR = 4.60, 95% CI: 2.34–9.03), histological grade (I, II vs III) (OR = 2.91, 95% CI: 1.92–4.40), metastasis (OR = 5.12, 95% CI: 3.47–7.55) and regional lymph node metastasis (OR = 2.47, 95% CI: 1.75–3.49). It was also significantly associated with poor overall survival (OS) (HR = 3.98, 95% CI: 2.20–7.21), progression/disease-free survival (PFS/DFS) (HR = 2.22, 95% CI: 1.80–2.73) and cancer-specific survival (CSS) (HR = 5.18, 95% CI: 2.21–12.13). Overall sensitivity and specificity of CTC detection assays were 0.35 (95% CI: 0.28–0.43) and 0.97 (95% CI: 0.92–0.99) respectively. In summary, our meta-analysis suggests that the presence of CTCs in the peripheral blood is an independent predictive indicator of poor outcomes for urothelial cancer patients. It can also be used as a noninvasive method for the confirmation of cancer diagnosis. More studies are required to further explore the role of this marker in clinical practice.

show abstract

“…Turker et al (19) determined the effectiveness of CTC in 22 metastatic and 12 Early stage breast cancer cases for prediction of progression free survival (PFS) and overall survival (oS) as an adjunct to standard treatment care in breast cancer management. CTC was positive in 3 (13.6%) patients before chemotherapy (CT) and 6 (27.3%) patients during CT in the metastatic subgroup whereas positive in only one patient in early stage subgroup before and during CT. CTC positivity was confirmed as a prospective marker in this study even with small patient group.…”

Section: Discussionmentioning

confidence: 99%

Circulating tumor cells in breast cancer: correlation with clinicopathological parameters, hormone profile and microrna polymorphisms

Bansal

Pujani²,

Misra³

et al. 2016

TJPATH

View full text Add to dashboard Cite

Objective: Circulating tumor cells are isolated tumor cells in the peripheral blood that serve as important prognostic indicators for many kind of tumors. The study was conducted to know the rate of detection of circulating tumor cells among breast cancer patients in comparison with benign breast diseases and control subjects and to know the association between CTC positivity and various clinicopathological parameters, hormonal profile and microRna polymorphisms. Material and Method:In the present case control study, we included 182 healthy controls, 108 cases of benign breast disease and 114 breast carcinoma cases. Various clinicopathological details of cases were recorded. Immunohistochemistry was performed for estrogen (ER) and progesterone receptors (PR) and Her-2 neu. Circulating tumor cells were analyzed using flow cytometry (EpCaM, CK, CD45). Genotypic frequency of micro Rna polymorphisms was determined by PCR-RFLP assay.Results: Circulating tumor cell positivity was observed in 11/114 (9.64%) breast cancer cases but absent in benign and control groups, and was significantly associated with tumor size, histologic type, tumor grade, metastasis and skin infiltration (p<0.05). Circulating tumor cell positivity did not show any correlation with the immunohistochemical profile. no significant associations between pre-miRna genetic variations miR-196a2 C/T (rs11614913), miR-146a G/C (rs2910164) and miR-499 T>C (rs3746444) polymorphisms and circulating tumor cell positivity were observed. Conclusion:The flow cytometry protocol for detection and molecular characterization of circulating tumor cells is a time and cost-effective technique, suitable for routine clinical use. However, more elaborate studies are needed to establish the findings as our study was limited by small sample size.

show abstract

Detection of Circulating Tumor Cells in Breast Cancer Patients: Prognostic Predictive Role

Cited by 9 publications

References 32 publications

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies

Circulating tumor cells in breast cancer: correlation with clinicopathological parameters, hormone profile and microrna polymorphisms

Contact Info

Product

Resources

About